RESUMO

Introduction: College students represent an important subpopulation of the United States, with over 19 million college students in the U.S. enrolled yearly. Methods: Descriptive analysis of the causes of death for all deceased students reported by the UW Dean of Students Office (DSO) between 2004 and 2018. We analyzed frequencies and yearly rates. Results: Our analysis shows that contrary to published data and national statistics for the relevant age groups, intentional by self-harm deaths lead causes of death in enrolled students from 2004 to 2018. Intentional by self-harm is the main cause of death in male students, younger students, and white students. "Other" causes of death is the main cause in female students, older students, and students of color. Conclusions: These results must be shared with different stakeholders across campus as well as with other universities in order to support and evaluate campus-wide prevention strategies for means restriction and environmental safety.

Introducción: Los estudiantes universitarios representan una subpoblación importante de los Estados Unidos, con más de 19 millones de matriculados anualmente. Sin embargo, hay pocos datos publicados sobre la mortalidad y causas de muerte en la población universitaria. El propósito de este estudio fue analizar las causas de muerte, basadas en datos de certificados de defunción, de estudiantes matriculados en University of Winconsin- Madison desde 2004 hasta 2018. Métodos: Análisis descriptivo de las causas oficiales de muerte de todos los estudiantes fallecidos reportados por la Oficina del Decano de Estudiantes entre 2004 y 2018. Se analizaron frecuencias y tasas anuales. Resultados: El análisis muestra que, contrariamente a los datos publicados y las estadísticas nacionales para los grupos de edad relevantes, las muertes intencionales por autolesión lideran las causas de muerte en los estudiantes matriculados entre esos años. Las autolesiones intencionales son la principal causa de muerte en los estudiantes varones, en los estudiantes más jóvenes y en los estudiantes blancos. Las causas incluidas en la categoría indicada como Otras son las principales en las estudiantes mujeres, en estudiantes mayores y en estudiantes de color. Conclusiones: Los resultados de este estudio deben compartirse con las diferentes áreas interesadas en todo el campus universitario y con otras instituciones universitarias, para apoyar y evaluar las estrategias de prevención, la aplicación de los medios de restricción y la seguridad ambiental.

Assuntos

RESUMO

This study investigated predictors of pneumococcal polysaccharide vaccine (PPV) use among older adults in Brazil. Respondents aged ≥50 from 2011 National Health and Wellness Survey in Brazil who had ever (vs never) received PPV were compared on comorbid risk, sociodemographics and vaccination behaviors. Logistic regression and decision tree analyses predicted PPV receipt as a function of the measures. Among 3195 respondents, 8.7% reported ever receiving PPV (10.4% among those at risk). Adjusting for covariates, adults classified as high or moderate risk had significantly greater odds of pneumococcal vaccination (odds ratios [ORs]: 2.42 or 1.36, respectively), as were those who received flu vaccinations (OR: 2.21) or were parents/guardians of a vaccinated child (OR: 6.48). In Brazil, child vaccination appears to be the dominant predictor of adult PPV uptake, followed by influenza vaccination. Higher disease risk was a significant predictor, but most older at-risk adults (89.6%) did not receive PPV.

Assuntos

RESUMO

OBJECTIVE: To estimate the morbidity and mortality of pneumonia in adults over 50 years of age in Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. METHODS: Local data sources were queried to estimate the number of hospitalized and outpatient pneumonia cases and deaths in the year 2009. Pneumonia cases were identified in adults aged ≥50 years using ICD-10 codes. The hospital case fatality rate (HCFR) by age corresponds to the percentage of mortality per hospitalization. RESULTS: Cases of hospitalized pneumonia (incidence per 100 000 inhabitants/year) in adults ≥50 years were: Argentina 39 674 (401.1); Brazil 225 341 (611.6); Chile 30 434 (738.5); Colombia 26 955 (326.6); Mexico 82 397 (413.1); Venezuela 31 601 (640.1). The number of hospital deaths (CFR%) were: Argentina 5099 (13%); Brazil 47 287 (21%); Chile 3072 (10%); Colombia 2981 (11%); Mexico 13 312 (16%); Venezuela 11 101 (35%). Cases of outpatient pneumonia (incidence per 100 000 inhabitants/year) were: Argentina 54 093 (546.8); Brazil 260 277 (706.4); Chile 33 173 (804.9); Colombia 27 713 (335.8); Mexico 83 354 (417.9); Venezuela 39 645 (803.0). The percentage of episodes treated as outpatient was 64% (range 57-80%) among those aged 50-64 years and 39% (range 8-56%) among those ≥85 years. Across countries, 51% of hospitalizations (range 42-63%) and 69% of deaths (range 65-72%) were in adults ≥75 years. CONCLUSIONS: Pneumonia is a common cause of hospitalization and mortality in adults in Latin America. Incidence increases substantially with increasing age, as does the likelihood of hospitalization and mortality.

Assuntos

RESUMO

Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects. Rodent models have been used in research on vaccines against T. gondii over the past decades. However, regardless of the vaccine construct, the vaccines have not been able to induce protective immunity when the organism is challenged with T. gondii, either directly or via a vector. Only a few live, attenuated T. gondii strains used for immunization have been able to confer protective immunity, which is measured by a lack of tissue cysts after challenge. Furthermore, challenge with low virulence strains, especially strains with genotype II, will probably be insufficient to provide protection against the more virulent T. gondii strains, such as those with genotypes I or II, or those genotypes from South America not belonging to genotype I, II or III. Future studies should use animal models besides rodents, and challenges should be performed with at least one genotype II T. gondii and one of the more virulent genotypes. Endpoints like maternal-foetal transmission and prevention of eye disease are important in addition to the traditional endpoint of survival or reduction in numbers of brain cysts after challenge.

Assuntos

RESUMO

Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects. Rodent models have been used in research on vaccines against T. gondii over the past decades. However, regardless of the vaccine construct, the vaccines have not been able to induce protective immunity when the organism is challenged with T. gondii, either directly or via a vector. Only a few live, attenuated T. gondii strains used for immunization have been able to confer protective immunity, which is measured by a lack of tissue cysts after challenge. Furthermore, challenge with low virulence strains, especially strains with genotype II, will probably be insufficient to provide protection against the more virulent T. gondii strains, such as those with genotypes I or II, or those genotypes from South America not belonging to genotype I, II or III. Future studies should use animal models besides rodents, and challenges should be performed with at least one genotype II T. gondii and one of the more virulent genotypes. Endpoints like maternal-foetal transmission and prevention of eye disease are important in addition to the traditional endpoint of survival or reduction in numbers of brain cysts after challenge.

Assuntos